^
Association details:
| Biomarker: | EGFR mutation + KIR3DL2 rs973541788 |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
Published date:
07/29/2023
Excerpt:
We sequenced tumor exomes from 135 lung cancer patients (79 with EGFR-wildtype (WT), 56 with EGFR-mutant tumors) enrolled in the ALCAPONE trial...A similar effect was found for the rs973541788 (c.1156C > G, p.(Gln386Glu)) polymorphism in the KIR3DL2 gene: worse PFS for patients with mutant tumors compared to that of patients whose tumors did not harbor this variant (HR = 2.32 [1.27–4.24] p = 0.005)...
DOI:
https://doi.org/10.1186/s12943-023-01829-4
Trial ID:
